Abbott To Rally Over 31%? Here Are 10 Top Analyst Forecasts For Friday
Key takeaways
- Rothschild & Co upgraded Abbott Laboratories (NYSE: ABT) from Neutral to Buy and lifted its price target from $119 to $127, an 8‑point increase.
- Price target: $127
- Previous target: $119
- Increase: 8 points
What happened
Rothschild & Co upgraded Abbott Laboratories (NYSE: ABT) from Neutral to Buy and lifted its price target from $119 to $127, an 8‑point increase.
Why it matters
The upgrade signals stronger confidence from a major research house, suggesting that Abbott’s earnings outlook and product pipeline may be more favorable than previously thought.
Short-term and longer-term
Short-term. Short‑term traders should watch for a price reaction to the target lift and the upcoming earnings announcement on Friday.
Longer-term. Investors should note that the upgrade reflects confidence in Abbott’s long‑term growth drivers, including its expanding specialty drug portfolio and potential new product launches, which could support sustained upside…